eLetters

117 e-Letters

published between 2010 and 2013

  • Needed number of events for logistic regression analysis
    Tomoyuki Kawada

    Dear Editor,

    I read with great interest the paper by van Sijl et al., (1) a 3-year longitudinal study by following patients with rheumatoid arthritis (RA) to know the effect of the estimated renal function on cardiovascular (CV) events. Out of 330 participants, 23 had CV event (7%). They mentioned the study limitation of low statistical power derived from small number of CV event and restriction of confounding va...

    Show More
  • How reliable is the diagnosis of very early rheumatoid arthritis in the multicentre real life prospective study as a predictor of remission?
    henning zeidler

    Dear Editor, Gremese et al. conclude from the real life prospective study performed in three early arthritis clinics that 12 weeks disease duration and an early intervention with DMARD represent the most significant opportunities to reach remission of RA. Moreover, it is supposed that vera early rheumatoid arthritis (VERA) represents a window of opportunity in terms of cost saving.

    A high level of confidence in t...

    Show More
  • Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors
    Xavier Mariette

    Dear Editor,

    Dear Editor,

    We recently published a meta-analysis of malignancy rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors (TNF-I). [1] Whilst there was no increase in the rates of all-site malignancy or lymphoma, there was an increased risk of non-melanoma skin cancer (NMSC) (1.45, 95% CI 1.15 to 1.76).

    The skin cancer analysis incl...

    Show More
  • DMARDs combination or biological therapy in rheumatoid arthritis patients
    Carlos Abud-Mendoza

    Dear Editor,

    We read with interest the paper by De Jong PH et al.,(1) a single blinded clinical trial which reports that triple disease modifying antirheumatic drugs (DMARDs) induction therapy is better than methotrexate (MTX) monotherapy in early rheumatoid arthritis (RA).

    Our Hospital is located in San Luis Potosí (Mexico) and our cohort includes low income patients without any opportunities for biological th...

    Show More
  • Seasonal effects of first symptoms on short-term versus long-term outcome in early arthritis
    Maurizio Cutolo

    Dear Editor,

    We read with great interest the letter from de Rooy et al. published in the last issue of the Journal (1).

    By analyzing the conclusions of this investigation in connection to another recent report about the real onset of arthritis symptoms during winter or spring and related more radiographic joint damage after 1 year, it seems that the authors found slightly different results that need some...

    Show More
  • A simple 'instrument' for memorizing the 11 features of axial spondyloarthritis (axSpA)
    Anand Malaviya
    Dear Editor,

    For the classification of axial spondyloarthritis (axSpA) Assessment of SpondyloArthritis international Society (ASAS) criteria are to be applied in patients with back pain of > 3 months and age at onset of back pain <45 years who have:
    (1) Sacroiliitis on imaging (definite sacroiliitis according to modified New York criteria OR active {acute}) inflammation on MRI highly suggestive of sacroiliitis assoc...

    Show More
  • HIGH SERUM IL-15 IS ASSOCIATED TO INCREASED LEVELS OF TOTAL RANKL. COMMENT ON AN ARTICLE BY KNEVEL ET AL.
    Isidoro Gonzalez-Alvaro
    Dear Editor,

    We have read with interest the article by Knevel et al, entitled “Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study” published on-line on March 22, 2012.1 The authors describe an elegant candidate gene study using four datasets of European rheumatoid arthritis (RA) patients with longitudinal radiological data, which let them conclude that genetic...

    Show More
  • Blocking IL-1 in SAPHO syndrome
    Matteo Colina

    Dear Editor,

    We read with great interest the article by Wendling et al. published online on January 4, 2012 in Annals of The Rheumatic Diseases, reporting a case series of SAPHO patients treated with anakinra (1). Some time ago, we firstly described a dysregulation of the P2X7 receptor-inflammasome axis in a patient with SAPHO syndrome successfully treated with anakinra, suggesting that interleukin-1 (IL-1) was very...

    Show More
  • Letter about the paper "Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study." by M Sebastianni.
    Sophie Blaise
    Dear Editor,

    We read with interest the paper of M Sebastianni et al about the predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis(1). The authors suggest that the CSURI score "can represent a feasible and reliable clinical tool in the routine evaluation of patients". However, we feel this report raises serious issues concerning the reproducibility of the methodology. When calculating the score, the num...

    Show More
  • Isn't age a factor?
    Matthew L Grove

    Dear Editor,

    Table 1 shows that PMR patients were significantly older than comparison subjects. Yet age wasn't included in the univariate or multivariate logistic regression models.

    A personal bugbear around the misdiagnosis of PMR is the misapplication of the label to relatively young patients without adequate clinical due diligence to exclude mimicking conditions. Since the incidence of PMR rises steep...

    Show More

Pages